Fisher Asset Management, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 138 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.

Quarter-by-quarter ownership
Fisher Asset Management, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$10,513,977
-32.1%
275,235
-35.9%
0.01%
-33.3%
Q2 2023$15,485,536
-6.2%
429,319
-0.7%
0.01%
-10.0%
Q1 2023$16,509,880
+66461.4%
432,309
-0.8%
0.01%
-41.2%
Q4 2022$24,804
-99.9%
435,917
-36.7%
0.02%
-15.0%
Q3 2022$27,243,000
-39.0%
689,000
-32.1%
0.02%
-37.5%
Q2 2022$44,673,000
+19.0%
1,015,289
+7.8%
0.03%
+45.5%
Q1 2022$37,548,000
-0.9%
941,514
-0.1%
0.02%
+4.8%
Q4 2021$37,907,000
-7.3%
942,730
-6.2%
0.02%
-16.0%
Q3 2021$40,901,000
-2.5%
1,005,438
+8.8%
0.02%
-3.8%
Q2 2021$41,946,000
+12.0%
923,714
+2.9%
0.03%0.0%
Q1 2021$37,441,000
-3.7%
898,077
-1.4%
0.03%
-10.3%
Q4 2020$38,897,000
+55.1%
910,715
-4.6%
0.03%
+31.8%
Q3 2020$25,075,000
-11.5%
954,157
-9.7%
0.02%
-21.4%
Q2 2020$28,329,000
+43.9%
1,056,671
-3.5%
0.03%
+16.7%
Q1 2020$19,693,000
-6.1%
1,094,671
-7.4%
0.02%
+14.3%
Q4 2019$20,969,000
+15.6%
1,182,663
+1.1%
0.02%
+5.0%
Q3 2019$18,145,000
-9.2%
1,169,916
+0.6%
0.02%
-9.1%
Q2 2019$19,983,000
-28.2%
1,163,160
-35.7%
0.02%
+22.2%
Q1 2019$27,829,000
+119.7%
1,807,609
+108.8%
0.02%
+5.9%
Q4 2018$12,668,000
+55.9%
865,919
+93.6%
0.02%
+70.0%
Q3 2018$8,128,000
+6.2%
447,338
-1.4%
0.01%0.0%
Q2 2018$7,653,000
-21.6%
453,652
-8.9%
0.01%
-23.1%
Q1 2018$9,756,000
-14.1%
498,014
-11.1%
0.01%
-13.3%
Q4 2017$11,353,000
+12.1%
560,373
-3.9%
0.02%
+7.1%
Q3 2017$10,131,000
+28.7%
583,221
-5.0%
0.01%
+16.7%
Q2 2017$7,872,000
-1.5%
614,021
-0.4%
0.01%
-7.7%
Q1 2017$7,990,000
+22.0%
616,511
-7.0%
0.01%
+18.2%
Q4 2016$6,549,000
-25.2%
662,811
-8.6%
0.01%
-31.2%
Q3 2016$8,758,000
+33.0%
725,0110.0%0.02%
+33.3%
Q2 2016$6,583,000
-22.3%
725,011
+2.4%
0.01%
-25.0%
Q1 2016$8,472,000
-30.9%
707,7800.0%0.02%
-33.3%
Q4 2015$12,266,000
+29.0%
707,7800.0%0.02%
+20.0%
Q3 2015$9,505,000
-43.2%
707,780
-4.5%
0.02%
-39.4%
Q2 2015$16,731,000
+53.6%
740,955
-2.9%
0.03%
+50.0%
Q1 2015$10,892,000
+48.0%
762,7800.0%0.02%
+46.7%
Q4 2014$7,361,000
+6.1%
762,7800.0%0.02%0.0%
Q3 2014$6,941,000
-11.3%
762,780
-3.7%
0.02%
-6.2%
Q2 2014$7,823,000791,7600.02%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2015
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders